Drug intelligence / Profile preview

Libogen

Development stage: Unknown
Lead developer: Trigen Pharma
Administration: Oral

Overview

**Libogen** is an oral capsule marketed by Trigen Pharma as a modern Traditional Chinese Medicine product for men's health. Trigen Pharma states that it is approved by China's Ministry of Health under registration number 0055 for decreased libido, impotence, general weakness, and related male health problems. Its active composition and molecular mechanism of action are not publicly specified in the identified source material. ([trigenpharma.com](https://trigenpharma.com/))

Brand names: Libogen
Other names: Libogen Capsule

Beyond the preview

Go deeper on Libogen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libogen.

Explore the full profile